Chrome Plugin Live! Redefine the way you read FinTwit š Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
RFL
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Quote Panel
Key Metrics
Relative Strength
RFL
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Earnings Growth
YoY
Current
Estimates
Q1.23
N/A
-0.13
vsĀ -0.12
Q2.23
N/A
-0.06
vsĀ -0.28
Q3.23
+125%
0.06
vsĀ -0.24
Q4.23
N/A
-0.08
vsĀ -0.22
Q1.24
N/A
-0.08
vsĀ -0.13
Q2.24
N/A
-1.36
vsĀ -0.06
Q3.24
N/A
-0.19
vsĀ 0.06
Q4.24
N/A
-0.37
vsĀ -0.08
Q1.25
N/A
-0.06
vsĀ -0.08
Q2.25
N/A
-0.19
vsĀ -1.36
Sales Growth
YoY
Current
Estimates
Q1.23
-94%
70KĀ vsĀ 1.1M
Q2.23
-92%
71KĀ vsĀ 875K
Q3.23
-1%
68KĀ vsĀ 69K
Q4.23
-3%
68KĀ vsĀ 70K
Q1.24
-3%
68KĀ vsĀ 70K
Q2.24
+373%
336KĀ vsĀ 71K
Q3.24
+143%
165KĀ vsĀ 68K
Q4.24
+88%
128KĀ vsĀ 68K
Q1.25
+13%
77KĀ vsĀ 68K
Q2.25
+8%
362KĀ vsĀ 336K
Return on Equity
QoQ
Q1.23
-3%
-0.03
vsĀ -0.05
Q2.23
-2%
-0.02
vsĀ -0.03
Q3.23
+1%
0.01
vsĀ -0.02
Q4.23
-4%
-0.04
vsĀ 0.01
Q1.24
+6%
0.06
vsĀ -0.04
Q2.24
-38%
-0.38
vsĀ 0.06
Q3.24
-5%
-0.05
vsĀ -0.38
Q4.24
-12%
-0.12
vsĀ -0.05
Q1.25
-7%
-0.07
vsĀ -0.12
Q2.25
-6%
-0.06
vsĀ -0.07
Institutionnal Ownership
QoQ
Q1.23
46
46
vsĀ 43
7%
Q2.23
45
45
vsĀ 46
-2%
Q3.23
42
42
vsĀ 45
-7%
Q4.23
42
42
vsĀ 42
NA
Q1.24
42
42
vsĀ 42
NA
Q2.24
41
41
vsĀ 42
-2%
Q3.24
30
30
vsĀ 41
-27%
Q4.24
32
32
vsĀ 30
7%
Q1.25
37
37
vsĀ 32
16%
Q2.25
42
42
vsĀ 37
14%
Forecast
2025-Revenue
2025-EPS
2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
N/A(N/A)
Number of analyst
N/A
Last analyst upgrade/downgrade
No Data Available
Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
NYSE
Unprofitable
Unprofitable
-0.01Ā ( -0.75%)
After-hours 1.37$
0.04 (3.01%)
Relative Strenght
4
Volume Buzz
-4%
Earning Acce
No
Dist 52w H.
58%